

PROGRAMME

Wednesday 17th May – Day One

8:00 am – 9:00 am	Registration			
9:00 am – 9:30 am	Opening and Welcome Conference Room II			
9:30 am – 10:15 am	Keynote Presentation: Kerstin Stenius: Towards control by management? On alcohol and drug problems in the history of Nordic welfare Conference Room II Chair: Vibeke A. Frank			
10:15 am – 10:45 am	MORNING TEA			
Session Theme	Drug policy differentiation	Policy responses to drug problems	Debating drugs in media	New psychoactive substances
	Conference Room II	Room A	Room C	Room D
Discussant chair	Vibeke A. Frank	Nicola Singleton	Steven Jonas	Peter Reuter
A 10:45 am – 12:15 pm	Panel 1: Drug policy differentiation: accommodating diversity and marginality Panelists: Elizabeth Ettorre Emma Wincup Daniel Bear Aileen O’Gorman Aims: Drug use by women, minority ethnic and marginalised groups is differentially stigmatised and problematised. These same social groups experience disproportionate levels of drug-related harms. Despite this, drug policies focus on addressing individual drug-using behaviours, through law enforcement, treatment, and outreach, as if these behaviours were context free and unaffected by structured inequalities. Rarely, in the development of drug policy, is the unequal experience of harms predicated by gender, race and class acknowledged or addressed. Moreover, the implementation of these policies can lead to harms which are disproportionately felt by these social groups. The presentations in this panel will explore the differentiated impact of drug policies and drug-related harms on women, trans men and women, black and minority ethnic groups, and marginalised socio-economic groups and communities. Drawing on case studies from their research, panellists will frame their presentations around the following questions: what is the impact of criminal justice; public health; and recovery approaches to drug policy on these social groups? How can drug policies best address difference, marginality and intersectionality	<u>Alison Ritter</u> , Caitlin Hughes, Kari Lancaster, Rob Hoppe Drug detection dogs seen through the eyes of the Advocacy Coalition Framework compared to Multiple Streams: the science-policy interface	<u>Lena Eriksson</u> The needle exchange debate in Stockholm City Council and Swedish Parliament during the 21st century	<u>Robert Csák</u> , József Rácz How environmental factors can increase the risks of PWIDs - a case study of Budapest, Hungary
	<u>Claudia Rafful</u> , Orozco R, Rangel G, Davidson P, Gonzalez-Zúñiga P, Werb D, Beletsky L, Strathdee SA. Increased non-fatal overdose risk associated with involuntary drug treatment in a longitudinal study with people who inject drugs in Tijuana, Mexico	<u>Mauricio Coitiño</u> , Rosario Queirolo, <u>Alejandra Triñanes</u> Same laws, different messages: the framing effect on the press coverage of the regulation of cannabis and alcohol in Uruguay	<u>Rob Ralphs</u> and Paul Gray Caught in the act: The impact of the Psychoactive Substances Act on vulnerable users	
	<u>Alisa Pedrang</u> , Joseph Doyle, Alex Thompson, Paul Dietze, Mark Stoove, Jacqui Richmond, Judy Gold, Peter Higgs, Margaret Hellard ECI: A partnership to eliminate hepatitis C in Australia	<u>Marie Jauffret-Roustide</u> Drug consumption rooms: issues of social acceptability in French public debate <u>My Lilija</u> Drug discourses in Russian parliamentary debate	<u>Maurits Beltgens</u> Examining the impact of the UK blanket ban on psychoactive substances on the UK’s legal high market	
12:15 pm – 1:15 pm	LUNCH			

Wednesday 17th May – Day One

Session Theme	Harms, trends & pleasures Conference Room II	Comparative analyses of drug policy and drug use Room A	Drug policies and history Room C	Different drugs, different policies? Room D
Discussant chair	Esben Houborg	Axel Klein	Geoffrey Hunt	Aileen O'Gorman
B 1:15 pm – 2:45 pm	<p><u>Mark Monaghan</u>, Ian Hamilton</p> <p>Risk, benefits and realism: The implications of the absence of pleasure in public health campaigns and interventions around cannabis</p>	<p><u>Aysel Sultan</u></p> <p>Drug policies of Azerbaijan and Germany reflected in narratives of high-risk drug user adolescents</p>	<p><u>Robin Room</u></p> <p>Legalising after prohibition: alcohol's lessons for other drugs</p>	<p><u>Santiago Cunial</u></p> <p>Conflicts around Issues with low political salience: explaining the role of the Catholic Church in the debate on drug depenalization in Argentina (2009-2014)</p>
	<p><u>Peter Reuter</u>, Bryce Pardo; Jonathan Caulkins</p> <p>Can sentences for drug offenses credibly reflect differences in the harms of drugs?</p>	<p><u>Anke Stallwitz</u></p> <p>Community policy at the micro-social level: Utilizing community-mindedness to reduce violence in the Vancouver and the Stockholm drug scene</p>	<p><u>David McDonald</u>, Alison Ritter</p> <p>Innovations in drug policy interventions over the past decade: an overview and assessment</p>	<p><u>Akash Sood</u>, Atul Ambekar, Ashwani Mishra</p> <p>Can economic analysis of household income and expenditure inform alcohol policies? Analysis of household data from nationally representative sample from India</p>
	<p><u>Bryce Pardo</u></p> <p>What relationship does access to cannabis have on the consumption of synthetic cannabinoids?</p>	<p><u>Luca Giommoni</u>, Peter Reuter, Beau Kilmer</p> <p>The perils of cross national comparisons of drug prevalence: the effect of survey modality</p>	<p><u>Mitch Librett</u></p> <p>Every doctor a cop; every cop a doctor</p>	<p><u>April Henning</u></p> <p>The escalating of the war on doping in 2016</p>
	<p><u>Jasmina Burdzovic Andreas</u>; Anne Line Bretteville-Jensen</p> <p>Ready, willing, and able: The role of cannabis use opportunities in understanding adolescent cannabis use</p>	<p><u>Majid Alaei</u>, Mahmoud Jahan Tigh</p> <p>A study on the prevalence of medication/polymedication abuse in Iran</p>	<p><u>Yun Huang</u></p> <p>"With a mill-stone about her neck": China's participation of the 1924-1925 Geneva Opium Conferences and its impacts</p>	
2:45 pm – 3:15 pm	AFTERNOON TEA			

Wednesday 17th May – Day One

Session Theme	Production and distribution of cannabis and methamphetamine Conference Room II	Harm reduction Room A	Methadone treatment Room C	Prison, treatment & drug use Room D
Discussant chair	Jonathan Caulkins	Susanne MacGregor	Bagga Bjerge	Emma Wincup
C 3:15 pm – 5:00 pm	<u>Steven Davenport</u> Do marijuana stores increase local traffic accidents? Evidence from Oregon	<u>Andy Guise</u> , Amen Hamida, Maria Luisa Mittal, Claudia Rafful, Peter Davidson, Daniel Werb Harm reduction, choice and pleasure in structural responses to injecting initiation; insights from qualitative research in the Mexico-U.S. border region	<u>Tim Rhodes</u> , James Ndimbii, Emmy Kageha, Frederick Owiti, Steffanie Strathdee, Andy Guise The becoming of methadone treatment in Kenya: A qualitative study of implementation	<u>Petr Zeman</u> , Michaela Štefunková, Šárka Blatníková, Kateřina Grohmannová, Tomáš Koňák, Ivana Trávníčková Treatment in an unfavourable setting: Specialized departments for drug users in Czech prisons
	<u>Simon Lenton</u> , Vibeke Frank, Monica Barratt, Gary Potter Growing practices and the use of chemical additives among a sample of small scale cannabis growers in three countries	<u>Kati Kataja</u> New practices of harm reduction? Sharing risk experiences of polydrug use on YouTube	<u>Roya Noori</u> , Masoud Lotfizadeh, Babak Moazen, Nazgol Mostafavinassab, Hooman Narenjiha Methadone maintenance treatment entry and retention among Iranian drug user women: A qualitative study in Iran	<u>Karen Duke</u> Producing the 'problem' of New Psychoactive Substances (NPS) in English prisons
	<u>Mafalda Pardal</u> "The difference is in the tomato at the end": understanding the role and practices of cannabis growers operating within Belgian cannabis social clubs	<u>Truong Tuan Dung</u> A qualitative and quantitative study to critically explore perceptions of harm reduction policy and practice in Vietnam	<u>Thu T.A. Vuong</u> , Nhu T. Nguyen, Nguyen B. Nguyen, Huy L. Pham, Huong Q. Nguyen From free service to co-payment model: Effects of the transition on patient adherence and service quality of the Methadone Maintenance Treatment program in Vietnam	<u>Yifen Lu</u> , Yichun Yu, and Chuen-Jim Sheu Evaluation of the deferred prosecution practice for drug abusers: An analysis with big data in Taiwan
	<u>Jason Ferris</u> The disruption of Australian domestic methamphetamine production: Analysis of pseudoephedrine-based medication sales data	<u>Steven Hayle</u> A social structural analysis of needle exchange policy in Canada and the UK	<u>Atul Ambekar</u> , Alok Agrawal, Ashwani Mishra, Ravindra Rao Do drug policies impede the availability of treatment of opioid dependence in India (and more so for non-injecting opioid users)? Analysis of epidemiological data from Punjab, India	<u>Torsten Kolind</u> Prison drug treatment: Increasing overlaps between social service and punishment
	<u>Modupe Onigbogi</u> , Omobola Ojo Willingness to join drug free clubs by elderly persons in Lagos, Nigeria	<u>Zahra Alammehrijdi</u> , Afsaneh Moradi Drug treatment and harm reduction programs for women in Iran: the first women-specific health policy in Western Asia	<u>Kristy Kruithof</u> , Matthew Davies, Emma Disley, Lucy Strang and Kei Ito Mapping the use of alternatives to coercive sanctions as a response to drug law offences and drug-related crimes across the EU	
5:30 pm – 7:30 pm	WELCOME RECEPTION ARoS Aarhus Art Museum			

Thursday 18th May – Day Two

8:30 am – 9:15 am	Registration			
9:15 am – 10:00 am	Keynote Presentation: Alejandro Madrazo Lajous: The Constitutional Costs of the War on Drugs Chair: Beau Kilmer Conference Room II			
10:00 am – 10:30 am	MORNING TEA			
Session Theme	Cryptomarkets Conference Room II	Performance and image enhancing drugs Room A	Alternative regulatory models for cannabis Room C	Developing drug supply indicators Room D
Discussant chair	Monica Barratt & Peter Reuter	Katinka van de Ven	Simon Lenton	Caitlin Hughes
D 10:30 am – 12:00 pm	<p>Panel 7: Cryptomarkets – recent empirical developments and theoretical perspectives</p> <p>Panelists: David Décaru-Héту Jakob Demant Monica Barratt Meropi Tzanetakis Judith Aldridge Rasmus Munksgaard Leigh Coney</p> <p>Aims: Cryptomarket research has matured in the last few years. A central group of researchers, many of whom comprise this panel, have been part of establishing methods and consolidating formative research (see special issue of IJDP, Volume 35, 2016). This panel presents new cryptomarket research considering long-term measurements, the meanings and uses of cryptocurrencies, the relevance for organized crime and the long standing relevant question of initiation of drug use. The aim is to bring together new research to further our understanding of the overall impact of cryptomarket emergence upon global drug markets and health/social outcomes.</p>	<p>Panel 8: HED policy panel I: Performance and image enhancing drugs</p> <p>Panelists: Katinka van de Ven Ask Vest Christensen Bertrand Fincoeur Anders Vinther</p> <p>Aims: To explore public health and law enforcement perspectives for regulating the illicit human enhancement drug (HED) market within the EU. A new kind of drug use has emerged with the growing prevalence of HEDs that have the potential to improve human attributes and abilities. People are using enhancement drugs for various lifestyle purposes such as to lose weight, to increase muscle strength and size, to look younger and/or to enhance sporting performance. In particular the use of performance and image enhancing drugs (PIEDs), a subset of HEDs, are growing in popularity in amateur and fitness sports. There is however little robust information on the use and supply of PIEDs which undermines the evidence-base for designing and implementing law enforcement measures, prevention, harm reduction initiatives and treatment. HED Panel I brings together knowledge of PIED use, problems and markets with a specific focus on the EU, whilst seeking to contribute to practice and policy.</p>	<p>Panel 5: Alternative regulatory models for cannabis in four countries</p> <p>Panelists: Jonathan Caulkins Beau Kilmer Tom Decorte Chris Wilkins John Clare</p> <p>Aims: There is growing popular support for the legalisation of cannabis in a number of countries around the world but only limited awareness of regulatory options other than the familiar and problematic commercial markets for alcohol and tobacco. There is a pressing need to provide greater detail and context to alternative non-commercial regulatory regimes for cannabis to inform public debate and political advocacy. This panel will present different regulatory regimes for cannabis from a number of countries. Each regulatory model reflects the specific legal, institutional and social environments of cannabis use in a country.</p>	<p>Panel 3: Developing drug supply indicators to improve policy monitoring, analysis and practice</p> <p>Panelists: Nicola Singleton Teodora Groshkova Roel de Bont</p> <p>Aims: The panel aims to highlight the challenges associated with using supply-side indicators for policy monitoring and analysis in a range of countries and regions and discuss potential ways of improving existing sources, expanding their use and identifying new indicators and data to provide a more complete and up-to-date picture of illicit drug production and markets and of their impacts. By describing some methodological development work currently underway it aims to stimulate the identification of opportunities for enhancing data collection and policy analysis in this area at both national and regional levels.</p>
12:00 pm – 1:00 pm	LUNCH			
1:00 pm – 1:30 pm	POSTER SESSION (room tba)			

Thursday 18th May – Day Two

Session Theme	Darknet and cryptomarkets Conference Room II	Cognitive enhancement drugs Room A	Selling drugs Room C	Drug monitoring and policy indexes Room D
Discussant chair	Peter Reuter & Monica Barratt	Jeanett Bjønness	Kim Møller	Claudia Costa-Storti
E 1:30 pm – 3:00 pm	Kristy Kruithof, Judith Aldridge, David Dé- cary-Héту, Megan Sim, Elma Dujso, <u>Stijn Hoorens</u> . Drug trade via cryptomarkets: trends, wholesale versus retail and shipping routes	Panel 9: HED policy panel II: Cognitive en- hancement drugs Panelists: Jeanett Bjønness Scott Vrecko Aleksi Hupli Gabija Didziokaitė Marte Ydema Aims: To explore public health and law enforcement perspectives for regulating the illicit human enhancement drug (HED) market within the EU. A new kind of drug use has emerged with the growing preva- lence of HEDs that have the potential to improve human attributes and abilities. One strategy for human enhancement is the use of cognitive enhancement drugs (CEDs); also often referred to as smart drugs, study drugs, nootropic or neuroen- hancers. These are drugs that are pur- ported to improve mental functions such as memory, intelligence, attention, and concentration. The most commonly used class of drug is stimulants. HED Panel II will bring together knowledge about use of and perceptions about CEDs among young people and contribute to a re- search-based future policy in the field.	<u>Cecep Mustafa</u> "She/he strives for justice that will be beneficial to the offender, although it will abandon legal certainty somewhat": the perceptions of Indonesian judges in sen- tencing minor drug offenders	<u>Peter Meylaks</u> , Eric Sevigny Development of a global policy index measuring national commitments to HIV prevention and treatment among people who inject drugs
	<u>Larissa J. Maier</u> , Monica Barratt, Jason Fer- ris, Adam Winstock Do zero tolerance drug policies promote NPS and darknet market use?		<u>Bernd Werse</u> , Dirk Egger "I don't do this because I want to get rich" – a comparative analysis of profit oriented drug-dealers in Germany	<u>Vivienne Moxham-Hall</u> , Caitlin Hughes, Alison Ritter The development and application of an Australian cannabis law index
	<u>Angus Bancroft</u> , Kim Masson 'Nice people doing shady things': The mor- ality of exchange in darknet cryptomar- kets		Judith Aldridge, <u>Lisa Williams</u> , Tom De- corte Can profitable drug selling activity be un- derstood as normalized? Drug cryptomar- ket sellers as drug reform activists	<u>Angelica Meinhofer</u> Prescription drug monitoring programs: the role of asymmetric information on drug availability and abuse
3:00 pm – 3:30 pm	AFTERNOON TEA			
3:30 pm – 4:15 pm	Keynote Presentation: Rosalie Liccardo Pacula: Into the weeds: Why details matter for properly evaluating the effects of changing marijuana policies Chair: Alex Stevens			Conference Room II

Thursday 18th May – Day Two

Session Theme	Different policy, different consequences Conference Room II	Treatment: complexity and comparison Room A	Mapping drug markets in different ways Room C	Costs of drugs Room D
Discussant chair	David McDonald	Marie Jauffret-Roustide	Alison Ritter	Beau Kilmer
F 4:20 pm – 5:30 pm	<p><u>Stephen Rolles</u>, Fiona Measham, Ole Rogeberg</p> <p>Using multi criteria decision analysis (MCDA) to assess different policy responses to non-medical heroin use</p>	<p><u>Bagga Bierge</u>, Jeppe Oute, Louise Christensen</p> <p>Complex cases – complex policies</p>	<p>Julian Broseus, Natacha Gentile, Simon Baechler, <u>Marie Morelato</u>, Pierre Esseiva</p> <p>Studying illicit drug markets through the analysis of its central component: how to provide intelligence by profiling law enforcement seizures</p>	<p><u>Laura Atuesta</u></p> <p>Towards an evaluable drug policy: Analysis of six focus groups in Mexico</p>
	<p><u>Daniel Mauricio Rico</u></p> <p>Alternative development and drugs supply reduction: who gets the benefits?</p>	<p><u>Jessica Storbjörk</u>, Jeanette Mugavin</p> <p>Events in problematic substance users' lives and paths to treatment: comparing the prohibitionist Sweden to the harm-minimizing Australia</p>	<p><u>Daan van der Gouwe</u>, Tibor Brunt, Magriet van Laar, Peggey van der Pol</p> <p>Purity, adulteration and price of drugs bought online versus offline in the Netherlands</p>	<p>Anne Line Bretteville-Jensen, Claudia Costa Storti, C. <u>Mikulic</u>, S. Trigueiros, F. Papamalis, P. Piscociu, Kattau</p> <p>Public expenditure on supply reduction policies</p>
	<p><u>Maria Luisa Mittal</u>, Claudia Rafful, Devesh Vashishtha, Patricia Gonzales-Zuniga, Peter Davidson, Dan Werb, Andy Guise</p> <p>Drug policy implications of pathways to initiation of injection drug use facilitated by people who inject drugs in Tijuana, Mexico</p>	<p><u>Lynda Berends</u></p> <p>Policy reform regarding the 'problem' of centralized assessment in Victoria's drug treatment sector</p>	<p>Jonathan Caulkins, Yilun Bao, Imane Fahli, Yutian Guo, <u>Krista Kinnard</u>, Mary Najewicz, Lauren Renaud.</p> <p>Big data on a big new market: Insights about suppliers and customers in Washington State's legal cannabis market</p>	<p><u>Claudia Costa Storti</u>, Charlotte Davies</p> <p>Estimating costs of drug treatment: main challenges and concerns</p>
	<p><u>Frank Renato Casas Sulca</u></p> <p>Scenarios and social actors as key determinants of drug policy in Peru: two comparative cases on coca leaf control</p>	<p><u>SeyedehNazgol Mostafavinasab</u>, Roya Noori, Omid Massah, Babak Moazen, Ali Farhoudian, Reza Daneshmand, Sepideh Aryanfard</p> <p>Women-only therapeutic community program and treatment needs in Iran: the first study from the most populated Persian Gulf country</p>	<p><u>Kim Moeller</u>, Sveinung Sandberg</p> <p>Putting a price on trust: a qualitative study of mid- and upper-level drug dealers' pricing decision</p>	
5:30 pm – 6:30 pm	ISSDP Annual General Meeting Room A			
7:00 pm – 9:30 pm	CONFERENCE DINNER at CANblau			

Friday 19th May – Day Three

8:30 am – 9:00 am	Registration			
9:00 am – 9:45 am	Keynote Presentation: Eugene Raikhel: Pathological desire: debating addiction and evidence in Putin's Russia Chair: Esben Houborg			
Session Theme	Development and drug policy	Researchers and drug use	Methodology and drug policy research	Research funding sources and conflicts of interest
	Conference Room II	Room A	Room C	Room D
Discussant chair	Alejandro Madrazo Lajous	Monica Barratt	Tom Decorte	Alison Ritter
G 9:50 am – 11:00 am	<p>Panel 10: New Perspectives on the intersection between development and drug policy</p> <p>Panelists: John Collins Aileen O’Gorman David Mansfield Alexander Soderholm</p> <p>Aims: This panel aims to present case-study based and novel analysis on the intersections between development and drug policy. It does such to influence the way in which issues associated with illicit drug markets are understood, and indeed their ‘root causes’, and to shape the policy interventions to these markets. Thus, the panel aims to examine how sustainably reduce the harms across the whole supply chain of illicit drugs.</p>	<p>Workshop: Are we ready to come out? Discretion, disclosure, identity and the drug researcher’s drug use.</p> <p>Monica Barratt with Judith Aldridge, Gary Potter and Anna Ross</p>	<p><u>Katrine Syppli Kohl</u></p> <p>Risk, knowledge and willful ignorance: Narratives of being knowledgeable in interviews with high-risk drug users</p> <hr/> <p><u>Rebecca Askew</u></p> <p>From apathy to activism: understanding drug takers perspectives on the law and policy</p> <hr/> <p><u>Peter Davidson</u>, Rebecca Fielding-Miller, Ricky Bluthenthal.</p> <p>Ethical collaborations between researchers and community organisations serving people who use drugs</p>	<p>Panel 4: Research funding sources and conflicts of interest: understanding diverse policy positions</p> <p>Panelists: Helen Keane Robin Room Alex Stevens Kerstin Stenius</p> <p>Aims: With this panel we hope to stimulate debate around the appropriate role (if any) of industry in funding policy-relevant drug research, with a view to informing future policy of the ISSDP (and IJDP) on accepting research that is industry-funded (where industry includes alcohol, tobacco, vaping, pharmaceutical, medicinal cannabis, private treatment and government industries that fund research).</p>
11:00 am – 11:20 am	MORNING TEA			

Friday 19th May – Day Three

Session Theme	The Uruguyan cannabis model	Drug trafficking	Drug user perspectives	Policing drugs in festival, club settings and on the streets
	Conference Room II	Room A	Room C	Room D
Discussant chair	Pablo Galain-Palermo	Gary Potter	Torsten Kolind	Daniel Bear
H 11:20 am – 12:50 pm	<p>Panel 2: The Uruguyan cannabis model: update and open issues</p> <p>Panelists: Pablo Galain Palermo Marcos Baudean Rosario Queirolo Gustavo Robaina</p> <p>On 10th of December 2013 the Uruguyan parliament passed law 19172 establishing a normative framework which allows control of the cannabis market. The law establishes a new approach to the distribution, consumption and commercialization of cannabis. On the one hand, it intends to contribute to the reduction of the risks and potential damages incurred by those persons who use cannabis for medicinal or recreational purposes (public health), and on the other hand as a measure to improve public safety and coexistence. The model proposes to implement a regulated distribution of cannabis in which the state will have a monopoly of the substance's distribution. Many things have changed in the country as a result of the new legislation. What are the preliminary results and lessons that can be learned from this period?</p>	<p><u>Sheryl McCurdy</u></p> <p>Pawns in Makran: Tanzanians, debt bondage, and drug trafficking strategies</p>	<p><u>Samhita Bhushan</u>, Atul Ambekar, Abhay Jain</p> <p>Attitudes and perceptions of retailers and consumers of legal cannabis (bhang) in India</p>	<p>Simon Lenton, Monica Barratt, <u>Jodie Grigg</u></p> <p>Drug detection dogs at Australian outdoor music festivals: Deterrent, detection and iatrogenic effects</p>
		<p><u>Allan Gillies</u></p> <p>The Evolution of State-Narco Networks in Post-Transition Bolivia (1982-1993): Governance, political order and processes of transition</p>	<p><u>Osasuyi Dirisu</u>, Darren Shickle, Helen Elsey.</p> <p>Perspectives on young cannabis users within the Nigerian policy context: The paradox of criminalization as a deterrence strategy</p>	<p><u>Caitlin Hughes</u>, Vivienne Moxham-Hall, Alison Ritter, Rob MacCoun, Don Weatherburn</p> <p>Going out in Sydney: a three month prospective study of the impacts of street-level policing on illicit drug use at outdoor music festivals and licensed entertainment precincts</p>
			<p><u>Paul Gray</u>, Rob Ralphs, Anna Norton.</p> <p>'Green heroin': Synthetic cannabinoid use amongst the homeless in the north of England</p>	<p><u>Thomas Friis Sogaard</u>, Esben Houborg</p> <p>Voices of the banished: young people's experiences of and resistance to nightlife zonal banning orders</p>
			<p><u>Charlotte de Kock</u>, Bert Hauspie, Ilse Derluyn, Tom Decorte, Wouter Vanderplas-schen, Julie Schamp.</p> <p>A qualitative exploration of perceived discrimination, ethnic identity and social network and their relation to substance use in people with a Turkish and Eastern-European migration background in Ghent, Belgium</p>	<p><u>M. Morales</u>, ML. Mittal, T. Rocha, C. Rafful, E. Clairgue, J. Arredondo, J. Cepeda, SA. Strathdee, L. Beletsky</p> <p>Translating drug policy reform: A qualitative study of police officer perspectives in implementing the Narcomeudeo law reforms in Tijuana, Mexico</p>
12:50 pm – 1:45 pm	LUNCH			

Friday 19th May – Day Three

Session Theme	Medical cannabis Conference Room II	New developments in harm reduction Room A	New theories in drug policy? Room C	Human rights and UN language Room D
Discussant chair	Rosalie Liccardo Pacula	Alex Stevens	Thomas Friis Søggaard	Angela Me
I 1:45 pm – 3:15 pm	<u>Davide Fortin</u> , Marcus Asplund The effects of full legalization on the medical cannabis market in Colorado: Evidence for prescription policy	Panel 6: New developments in harm reduction: panel of the ISSDP/ESC joint working group on European drug policy Panelists: Camille Stengel William Floodgate Fiona Measham Tristan Duncan Aims: Harm reduction is an approach that was developed in European countries, originally to counter the spread of blood borne viruses. In recent years, it has faced challenges, including new patterns of drug use, increases in drug-related deaths and competition from the 'recovery agenda' in some countries. This panel will present new theoretical and empirical work on harm reduction in European countries. It is a panel of the joint working group between the ISSDP and the European Society of Criminology	<u>Vanessa Gstrein</u> Ideation, social construction and drug policy: a scoping review	<u>Ediomo-Ubong Nelson</u> Criminalization of drug use and human rights: Narratives of police crackdowns in Uyo, Nigeria
	<u>Edgar Guerra</u> Prohibition or legalization. The dispute over medical use or recreational consumption of cannabis in Mexico		<u>Anna Ross</u> Developing a critical drug theory: Narrative, knowledge and participation	<u>Melissa Bone</u> Human rights, politics and power: for the case of the UK's Cannabis Social Club Movement
	<u>Sharon Sznitman</u> Do recreational cannabis users, unlicensed and licensed medical cannabis users form a distinct group?		<u>Eric A. Ratliff</u> "A totally different atmosphere": Co-producing drug contexts through narrative emplacement	Jamie Bridge, <u>Christopher Hallam</u> Dave Bewley Taylor, Marie Nougier, Martin Jelsma Edging forward: How the UN's language on drugs has advanced since 1990
	<u>Axel Klein</u> , Gary Potter The three betrayals of the medical cannabis grower: from multiple victimhood to reconstruction, redemption and agency			
3:20 pm – 3:45 pm	Conference Closing Ceremony and invitation to ISSDP 2018: Vancouver, Canada			